Clinical medicine profile
Metoprolol
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- History of asthma and related uncontrolled asthma, sick sinus syndrome, cardiogenic shock, phaeochromocytoma unless used with -blockers, bradycardia, metabolic acidosis, hypoglycaemia.
Precautions
- Asthma, chronic respiratory disease, bronchitis, raynauds disease, masking of hyperthyroidism, diabetes, myasthenia gravis, hepatic/renal impairment, avoid abrupt withdrawal in angina.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
100-400mg daily orally. 1.V inj: 5-15mg depending on indications
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Hypertension, Angina and myocardial infarction Clinical selection for Metoprolol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Bradycardia, bronchospasm, GI disturbances, heart failure, peripheral vasoconstriction, fatigue, insomnia, sexual impotence, hypoglycaemia, cold extremities, skeletal muscle weakness, dizziness, purpura.
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
Beta1-selective adrenoceptor blocking agent Mechanism is agent-specific.
Read complete mechanism
Beta1-selective adrenoceptor blocking agent Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| BETALOC ZOK | DAIMA BIASHARA / Wholesale Import | TABS 50MG * 30`S | KES 1,177.97Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| Betaloc Zok 25 mg Tablets | AstraZeneca UK Limited | Tablet 25mg | Unavailable |
| Betaloc Zok 50 mg Tablets | AstraZeneca UK Limited | Prolonged-Release Tablet 50mg | Unavailable |
| Betaloc ZOK 100 mg Tablets | AstraZeneca UK Limited | Prolonged-Release Tablet 100mg | Unavailable |
| Revelol XL 50 | Ipca Laboratories Limited | Film-Coated Tablet | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.